![]() |
市場調查報告書
商品編碼
1420138
南美洲和中美洲類器官市場預測至 2030 年 - 區域分析 - 按器官類型、應用、來源和類型South & Central America Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type, Application, Source, and Type |
南美洲和中美洲類器官市場預計將從2022年的1.3238億美元成長到2030年的6.5425億美元。預計2022年至2030年CAGR為22.1%。
專注於藥物發現活動推動南美洲和中美洲類器官市場
對新藥和先進藥物不斷成長的需求正在推動藥物發現和研究的整體步伐。根據 ClinicalTrials.gov 統計,2020 年臨床試驗研究總數估計為 356,282 項。休布雷希特研究所最近的一項調查表明,類器官可以透過識別不太可能從該藥物中受益的患者來使昂貴的藥物更具成本效益。全球範圍內越來越多的臨床試驗預計將推動對先進醫療技術(包括類器官模型)的需求。
此外,藥物發現中的類器官不僅限於癌症,它們還用於其他疾病,例如囊性纖維化、多囊性腎病變、小頭畸形以及腸道和氣道傳染病。例如,類器官可以概括器官的特性,例如器官結構和功能。此外,類器官可以恢復組織或器官的原始遺傳和表觀遺傳狀態,使它們適合基因編輯。各種研究顯示了將 CRISPR-Cas9 技術與類器官結合的積極成果,這為囊性纖維化的突破提供了更多機會。根據2020 年發表的一項研究“基於CRISPR 的腺嘌呤編輯器糾正囊性纖維化類器官生物庫中的無義突變”,囊性纖維化類器官生物庫代表了664 名患者,其中約20%理論上能夠有效修復無義突變透過腺嘌呤鹼基編輯器在囊性纖維化跨膜導體受體中。儘管基因編輯類器官在一些動物模型中取得了一些成果,但其效率明顯較低,成功率不高。因此,研究和開發基因編輯類器官的安全性、長期穩定性和功能性的方法至關重要。
此外,COVID-19 大流行引發了開發人類肺類器官模型的需求。例如,MilliporeSigma 開發了 3dGRO 人類肺類器官培養系統,使研究人員能夠控制、存取和複製器官組織,以培養人類肺上皮類器官模型,從而有助於在研究過程中獲得積極和成功的結果。因此,此類創新預計將為市場成長提供更重要的成長機會。
南美洲和中美洲類器官市場概述
南美洲和中美洲類器官市場分為巴西、阿根廷以及南美洲和中美洲其他地區。由於癌症病例數量的增加、政府措施的不斷增加以及類器官研究和開發的不斷增加,該地區的市場預計將成長。
南美洲及中美洲類器官市場收入及 2030 年預測(百萬美元)
南美洲和中美洲類器官市場細分
南美洲和中美洲類器官市場分為器官類型、類型、應用、來源和國家。
依器官類型,南美洲和中美洲類器官市場分為腸、肝、胃、胰臟、肺、腦、腎等。 2022 年,腸道部分在南美洲和中美洲類器官市場中佔據最大佔有率。
根據類型,南美洲和中美洲類器官市場分為儀器、消耗品和服務。 2022 年,消耗品領域在北美類器官市場中佔據最大佔有率。
根據應用,南美洲和中美洲類器官市場分為發育生物學疾病、傳染病病理學、再生醫學、藥物毒性和功效測試、藥物發現和個人化醫療等。 2022 年,發育生物學疾病領域在南美洲和中美洲類器官市場中佔據最大佔有率。
根據來源,南美洲和中美洲類器官市場分為多能幹細胞和器官特異性成體幹細胞。 2022 年,多能幹細胞細分市場在南美洲和中美洲類器官市場中佔有較大佔有率。
根據國家/地區,南美洲和中美洲類器官市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022 年,巴西在南美洲和中美洲類器官市場佔據主導地位。
Cellesce、InSphero、Merck KGaA、STEMCELL Technologies Inc 和 Thermo Fisher Scientific Inc 是南美洲和中美洲類器官市場的一些領先公司。
The South & Central America organoids market is expected to grow from US$ 132.38 million in 2022 to US$ 654.25 million by 2030. It is estimated to grow at a CAGR of 22.1% from 2022 to 2030.
Focus on Drug Discovery Activities Fuel South & Central America Organoids Market
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.
Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ's original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study 'CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,' published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids' safety, long-term stability, and functionality.
Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.
South & Central America Organoids Market Overview
The South & Central America organoids market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the increasing number of cancer cases, growing government initiatives, and rising research and development for organoids.
South & Central America Organoids Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Organoids Market Segmentation
The South & Central America organoids market is segmented into organ type, type, application, Source, and country.
Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the South & Central America organoids market in 2022.
Based on type, the South & Central America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the South & Central America organoids market in 2022.
Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held the larger share of the South & Central America organoids market in 2022.
Based on country, the South & Central America organoids market is segmented into the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America organoids market in 2022.
Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, are some of the leading companies operating in the South & Central America organoids market.